FOUNDED IN 2001 ON THE IDEA OF COMBINING THE PRINCIPLES OF SMALL-MOLECULE SYNTHESIS AND EVOLUTION-BASED SCREENING
Focusing on delivering breakthrough medicines for treatment of cancer and inflammatory diseases
Nuevolution is a Scandinavian biopharmaceutical company focused on developing drug treatments for human diseases within oncology and chronic inflammatory diseases. We have set our focus and objectives to be:
Realization of efficacious, safer, tablet based, and lower cost medicines, for treatment of severe chronic inflammatory diseases like e.g. multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis (PsO), inflamed fatty liver (NASH) and chronic inflamed colon or intestine (IBD) where significant unmet medical need remains.
Realization of programs enabling future medicines in immuno-oncology, effectively reactivating the cancer patient’s own immune system, when this has been ‘silenced’ by tumour cells.
Realization of programs enabling personalized medicine (medicine fitting the individual patient) for treatment of cancer through identification of drugs, which selectively and safely eliminate the biological pathways upon which the tumour cells (of the individual patient) are dependent for survival and growth.
Nuevolution is the inventor of Chemetics®, a patent protected drug discovery platform, which enables efficient discovery of novel small molecule (tablet based) drug candidates. The platform provides access to screening of billions of molecules and efficient optimization of drug properties in the process of identifying the drug candidate. Chemetics® has been successfully applied in numerous drug discovery and technology licensing partnerships against tough-to-drug biological disease targets, where other approaches had failed.
Over the years, Nuevolution has entered 15 agreements with partners including Novartis, Janssen Biotech, Inc. (Johnson & Johnson), Boehringer Ingelheim, GlaxoSmithKline, Merck & Co (MSD), Lexicon Pharmaceuticals, as well as world-class oncology research institutions, such as Cancer Research Technology and Institute of Cancer Research.
The Company was founded in May 2001 and is headquartered in Copenhagen, Denmark. Nuevolution AB (publ) is listed on NASDAQ First North Premier (NUE.ST). Forty dedicated and experienced full time employees work at Nuevolution.
Our name, Nuevolution, – ‘evolution of novel’ – composed from the words ‘nuevo’ and ‘evolution’, encompasses the core of our technological capability. Harnessing the encoding power of DNA, we are able to screen biological disease targets and identify small molecules for tablet-based medicines, in a process applying conditions of ‘survival of the fittest’ as coined by Herbert Spencer (inspired after reading Darwin’s ‘On the Origin of Species’).
Our logo is a reflection of key elements constituting Nuevolution – organic chemistry (the hexagon), drug development (geometrical complexity), hope for diseased (the star) and creating value (the ruby gem).